Spermosens AB ("Spermosens" or the "Company") today held its Annual General Meeting in Lund. The following resolutions were adopted:

• The Annual Report and Auditor's Report for the financial year 2024 were presented.
• CEO Tore Duvold provided a summary of the Company's operations and key developments over the past year.
• The meeting resolved to adopt the income statement and balance sheet for 2024, and the Board of Directors was discharged from liability for the financial year.

Election of Board of Directors and Auditor
The meeting reelected the following members to the Board of Directors: Søren Melsing Fredriksen, Ingela Liljeqvist Soltic, Kushagr Punyani, Christina Östberg Lloyd and Ulrik Spork. Ulrik Spork was appointed Chairman of the Board.

Forvis Mazars AB was appointed as the Company's auditor.

For more information, please contact:
Tore Duvold, CEO
info@spermosens.com

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com